Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 7/20 | 0.42 |
| ▸ | CACNA1H | O95180 | 9/20 | 0.39 |
| ▸ | CACNA1G | O43497 | 4/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 3/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | CBFB | Q13951 | 1/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4177229 | 0.92 | NPBWR1 (0.40) | NPBWR1DGAT1KCNH2SOAT1 | |
| SCHEMBL4184625 | 0.92 | CACNA1H (0.44) | NPBWR1CACNA1HCACNA1GCACNA1CDGAT1 | |
| SCHEMBL4174460 | 0.71 | CBFB (0.62) | NPBWR1CACNA1HCACNA1GCACNA1CDGAT1 | |
| SCHEMBL30519379 | 0.70 | CASP1 (0.58) | — | |
| SCHEMBL2413106 | 0.70 | CASP1 (0.58) | — | |
| SCHEMBL4190036 | 0.68 | CBFB (0.48) | NPBWR1CACNA1HCACNA1GCACNA1CCBFB | |
| SCHEMBL4184828 | 0.68 | CBFB (0.46) | NPBWR1CACNA1HCACNA1GCACNA1CDGAT1 | |
| SCHEMBL4193310 | 0.68 | SMN1; SMN2 (0.45) | NPBWR1DGAT1KCNH2 | |
| SCHEMBL16121159 | 0.68 | CACNA1H (0.54) | NPBWR1CACNA1HCACNA1GCACNA1CCBFB | |
| SCHEMBL16121157 | 0.67 | CACNA1H (0.50) | NPBWR1CACNA1HCACNA1GCACNA1CCBFB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9199965-B2 | Benzoimidazole derivatives and pharmaceutical composition comprising the same | DAEWOONG CO., LTD. (KR) | 2015-12-01 | — | — | US | disclosed |
| EP-1861387-B1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | DAE WOONG PHARMA (KR) | 2014-04-16 | — | — | EP | disclosed |
| US-20090018124-A1 | Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018124-A1 | Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same | TRPV1, TRPA1, BDKRB2 | NPBWR1 56/4885CACNA1H 522/4885CACNA1G 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.